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Introduction
Pertussis (whooping cough) is a respiratory tract infec-
tion characterised by a paroxysmal cough, caused by 
Bordetella pertussis, a gram negative coccobacillus. The 
disease can affect individuals of all ages, even though 
the most severe complications and mortality occur more 
frequently in early infancy. Bordetella pertussis is an 
exclusively human pathogen; hence elimination of the 
disease by mass vaccination should theoretically be an 
achievable objective, even though neither natural infec-
tion nor vaccination confer permanent immunity. The 
implementation of well-conducted vaccination strategies 
in various countries has not prevented the re-emergence 
of pertussis [1, 2] particularly in 2 age groups: those over 
10 years and infants aged less than 5 months [3]. 
This is the reason why many countries, including Italy, 
have introduced antipertussis vaccinations for adoles-
cents into the national immunisation schedule.
Among the strategies proposed to control pertussis and 
decrease pathogen circulation, with the aim of reducing 
the burden of disease in children that have not yet been 
vaccinated, the international literature presents a number 
of strategies. Besides the vaccination of adolescents and 
the replacement of decennial antitetanus and antidiphthe-
ria booster vaccinations with a trivalent diphtheria, teta-
nus and pertussis vaccine, the “cocoon” strategy is pro-
posed, with the aim to indirectly protect newborn infants 
through the immunisation of a target population of adults, 
represented by parents and other potential close contacts, 
such as grandparents and healthcare workers [4-6]. 
The goal of this paper is to evaluate the rationale and 
potential of “cocooning” as a complementary strategy to 
universal infant and adolescent’s antipertussis vaccina-
tion in order to reduce the risk of pertussis in newborn 
infants, highlighting which healthcare providers are 
expected to be involved in its implementation.
Epidemiology
How epidemiology of pertussis in italy 
and worldwide Has cHanged witH tHe 
implementation of universal infant vaccination
Pertussis is a highly-contagious infectious respiratory 
disease (attack rate greater than 80-90% among non-im-
munised family contacts [7]). Man is the only known 
reservoir of the bacterium that is transmitted from 
person to person through the large respiratory droplets 
generated by coughing or sneezing (Flugge’s droplets). 
Onset of the actual disease follows an incubation period 
varying between 5 and 21 days, during which no par-
ticular symptoms are shown. The course of the disease 
is 6-8 weeks, and may be divided into three distinct 
periods: catarrhal, paroxysmal and convalescence. As 
shown in Table I, the potential complications of pertus-
sis are represented by hypoxia, pneumonia, convulsions, 
encephalopathy and death. Children aged less than one 
year are at high risk of such complications and hospi-
talisation [5]. 
The bacterium performs its pathogenic action bind-
ing to respiratory tract’s epithelial cells through 
adhesins and above all with the production of highly 
immunogenic toxins: the pertussis toxin, which 
causes cellular lesions, filamentous haemagglutinin 
and pertactin [7]. 
Notification of pertussis is mandatory in Italy. The 
introduction of infant vaccination in the 1960s was fol-
lowed by a reduction in incidence of the disease up until 
the 1970s, but with increased incidence in the 1980s. 
This is mainly due to the non-homogeneous offer of 
vaccination at Region level, which limited vaccination 
coverage at the national level to around 40% until the 
1990s [8,  9]. With the introduction of combined acel-
lular vaccines (less reactogenic compared to whole cell 
vaccines) in the mid 1990s and the recommendation 
of a primary cycle with 3 doses, vaccination coverage 
reached 88% for the cohort born in 1996 [10] and, after 
the pertussis vaccine became free of charge in 2002, 
over 96% in 2008 [11]. 
As a matter of fact higher vaccination coverage influ-
enced pertussis epidemiology in Italy. A retrospective 
Tab. I. Complications of pertussis in children aged < 12 months in 
the uSA (2000-2004) [5].
Complication Number of subjects %
hospitalisation 6114 62.8%
Apnoea 5454 55.8%
pneumonia 1063 12.7%
Convulsions 146 1.5%
death 92 0.8%
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study [12] has assessed the trend of pertussis incidence 
rates (ISTAT and Ministry of Health data) within the 
period 1955-2002 and the seroprevalence of whooping 
cough using samples of serum collected between 1996 
and 1997 for the ESEN (European Sero-Epidemiology 
Network) project. The results highlight a progressive 
reduction in the incidence of pertussis among children 
under the age of 4 years, but a significant increase in 
the 5 to 9 year old (1.5 fold) and 10 to 14 year old age 
groups (over 3 fold) (Fig. 1).
The same study documented a shift in the median age of 
acquiring pertussis, increasing from 3 years in the period 
1971-89 to 6 years for the period 1998-2002 [12]. With 
regard to the serological investigation, the seropreva-
lence of subjects with levels of IgG antibodies against 
pertussis toxin (PT) above 2 EU/ml (minimum detection 
level) has been 77.6%. Furthermore, the high percentage 
of subjects aged between 10-14 years and 15-19 years 
with high anti-PT antibody titres suggests that pertussis 
is still circulating among adolescents. These conclusions 
have been confirmed by a recent multicentre study con-
ducted in several Italian geographical areas [13] evaluat-
ing humoral and cell-mediated immunity in adolescent, 
adult and elderly subjects, populations that in the past 
were deemed not to be involved in the circulation of the 
pathogen, and for which a booster of reduced antigen 
content vaccine might be something to consider. 
Although it has drastically reduced the incidence of the 
disease, the introduction of universal infant vaccina-
tion is not in itself enough to eliminate or adequately 
control pertussis. Inadequate vaccination coverage, loss 
of immunity and the lack of boosters in adolescents and 
adults are the main causes [14] (Fig. 2). 
In adolescents and adults, diagnosis is frequently de-
layed due to atypical clinical manifestations, lack of 
awareness by medical staff with the result of a potential 
risk of sub-diagnosis [15] and transmission of the infec-
tion for several weeks [16]. The increased incidence 
of pertussis in adolescents and adults results in an in-
creased risk of transmission of the infection to infants 
before they have initiated or completed the primary 
vaccination cycle. 
The present hypothesis is supported by data reporting 
number of cases of pertussis hospitalized in the 1st year 
of life. In fact, according to hospital discharge reports 
database, in Italy, about 100 hospitalisations are record-
ed per year in children under the age of one year [17] 
(Fig. 3), while a retrospective study conducted in Sicily 
Fig. 1. proportional distribution of pertussis cases according to age group within low (1971-89), intermediate (1990-1996) and high (1998-
2002) vaccination coverage periods (from rota et al., 2005 [12], by permission). 
Fig. 2. Cycle of pertussis transmission between adults and chil-
dren.
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Region in 2002 [18], found that 72% of hospitalized 
pertussis cases were in children too young to be fully 
vaccinated or in those that had received only the 1st vac-
cine dose (Fig. 4); moreover, among cases of babies too 
young to be vaccinated, the most important source of 
infection identified was an household member above 14 
years of age (Tab. II).
Italian data are similar to that observed in other coun-
tries with high infant vaccination coverage. 
In Europe, the EUVAC-NET surveillance project, in-
volving 16 European countries, has recorded a 115% 
increase in the incidence of cases in adolescents over the 
age of 14 years between 1998 and 2002 [19].
A retrospective study conducted in Spain analysed hos-
pital discharge reports between 2003 and 2007, conclud-
ing that from the 49 pertussis cases hospitalised within 
the period considered, 47 occurred in children under 
the age of 6 months, of which 23.4% had a complicated 
disease course and 3 died. In 65.3% of cases, the source 
of infection had been identified 
as a family member [20]. 
In France, where a pertussis sur-
veillance project has been active 
within a network of paediatric 
hospitals since 1996, 2878 cases 
of pertussis have been recorded 
in subjects under the age of 16 
years between 1996 and 2007. 
Of these, 1882 were in chil-
dren under the age of 6 months. 
An survey conducted among the 
household members of hospital-
ized infants showed that in 54% 
of cases, one of them reported 
prolonged coughing. The mean 
age of the family members iden-
tified as the source of infection 
rose from 19.6 years in 1996 to 
31.9 years in 2007 (significant 
difference), while the proportion 
of siblings reduced from 34% to 
19% over the same period [21]. 
Mortality during the period con-
sidered has been 2% (34 chil-
dren), of which, only 1 had re-
ceived 1 single dose of vaccine, 
in 13/16 in which it has been 
possible to trace the source of 
infection, it has been confirmed 
as one of the parents [21].
In the Unites States, where uni-
versal infant vaccination was 
introduced long before than in 
Italy, these phenomena are well 
documented. Considering the 
high levels of Diphtheria Tetanus 
acellular Pertussis (DTaP) vacci-
nation coverage, it has been esti-
mated that between 2001-2003, 
on average, there have been 98 
hospitalisations due to pertussis 
each year from every 100,000 
children between 0 and 5 months, 
compared to 12 cases/100,000 
children aged between 6 and 11 
months [22]. Of the 100 deaths 
recorded between 2000 and 
2004, 76 occurred in children 
aged less than 1 month [5]. One 
Tab. II.  Cases of pertussis in children not fully vaccinated due to their age. (from Cuccia et al., 
2004 [18], by permission).
Cases
No 
contact
Pediatrician
Family 
member 
0-5 years
Family 
member 
6-13 years
Family 
member 
≥ 14 anni
0 months 5 1 2
1 months 10 3 4 3
2 months 6 1 2 1 2
3 months 6 1 3 2
4 months 3 2 1
total 30 7 9 1 3 10
Fig. 4. hospitalised pertussis cases in Catania province in 2002 (from Cuccia et al., 2004 [18], 
by permission).
Fig. 3. number of hospital discharge reports with main diagnosis of pertussis in children aged 
less than 1 year.
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study investigating the source of infection reported that 
in 32% of cases, this was a family member [5].
Hence, there is growing evidence that adolescents and 
adults, in particular parents, are the main reservoir of 
infection for unvaccinated infants [23]. This is mainly 
associated with loss of immunity, indeed, both vaccina-
tion and natural infection cannot succeed in inducing 
a persistent immune response, as it is now extensively 
documented in various studies [24, 25]. A recent review 
of the literature reports that loss of immunity occurs 4-20 
years after natural infection, while the immunity acquired 
after vaccination lasts between 4 and 12 years [26]. 
The acquisition of this new knowledge regarding how 
the epidemiology of the disease has changed with the 
introduction of universal infant vaccination has lead 
many experts to recommend the administration of peri-
odic pertussis booster, with the aim of interrupting the 
disease cycle and reducing the frequency of cases of 
pertussis among adolescents and adults, thus reducing 
the risk of infection in infants that have not completed 
the primary vaccination cycle. 
Pertussis vaccines
The first vaccines containing whole, inactivated Borde-
tella pertussis cells were developed in the 1950s. How-
ever, although they dramatically reduced the incidence 
and complications of the disease, these vaccines were 
shown to be very reactogenic. Developing technology 
allowed the introduction of acellular vaccines, contain-
ing only some antigens from the bacterium [27]. 
Subsequent studies have confirmed that the number of 
anti-pertussis antigens included in the vaccine formula-
tion (from 1 to 5) is correlated with efficacy. In particu-
lar, it has been shown that the addition of pertactin to the 
pertussis toxin and to phytohaemagglutinin significantly 
increases the protection conferred by the vaccine [27]. 
Indeed, various studies have documented that anti-
pertactin antibodies have a crucial role in Bordetella 
pertussis opsonisation and phagocytosis [27].
A recent meta-analysis of 52 clinical studies has high-
lighted how the efficacy of 3-component acellular vac-
cines, with pertactin, is superior to that of 1 or 2 compo-
nent vaccines, without pertactin, being equal to 80-84% 
compared to 67-70% respectively. On the other hand, 
the addition of other antigens, such as those towards 
fimbriae 2 and 3, does not seem to further increase pro-
tective activity, being equal to 80 and 84% respectively, 
for 4 and 5 component vaccines (Fig. 5) [27, 28]. 
Nowadays, acellular pertussis vaccines with reduced 
antigenic content (dTap) are available for booster vac-
cinations in adolescents and in adults [5, 29-31].
These vaccines are much more tolerated than those at 
paediatric dose for which an increased risk of local ad-
verse events has been observed [30, 31] with increasing 
number of booster dose.
dTpa vaccines are highly immunogenic with regard to 
seroconversion rates and antibody titre [29, 30] towards 
pertussis, diphtheria and tetanus antigens. The immuno-
logical response to the 3 pertussis antigens in adults and 
the elderly has been studied in a trial evaluating subjects 
aged between 15 and 93; in the elderly population, even 
if the antibody titre level reached was inferior compared 
to the younger population, a strong booster response 
was elicited, since titres were raised 6-10 fold compared 
to the pre-vaccination value, supporting the develop-
ment of immunological memory. This data show how 
unvaccinated elderly subjects have a high probability 
of having been exposed to natural infection throughout 
Fig. 5. efficacy and safety of pertussis vaccines with different pertussis antigen composition in children ≤ 15 years of age: meta-analysis 
of 52 studies. 
*whO definition: laboratory confirmed pertussis in subjects with ≥ 3 weeks of spasmodic coughing and howling. **duration of coughing ≥ 1 week, laboratory confirmed.
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their lives, and hence pertussis vaccination acts as a 
booster [30].
With regard to efficacy data in adolescents, a reduced 
antigenic content vaccine, after a single booster dose, 
has been shown to induce an antibody response against 
the 3 pertussis antigens (PT, FHA, PRN) that was no 
less in comparison to children receiving 3 doses of the 
primary cycle [31]. 
Even in adolescents not previously vaccinated against 
pertussis, the administration of a single dose of dTpa 
vaccine has been shown to induce high responses in 
terms of seroconversion and increase in antibody titre 
against pertussis antigens, in showing that that adoles-
cents have been in contact with the pathogen over the 
course of their lives and that a single dose of vaccine has 
boosted the immunological memory and is well toler-
ated by this population of subjects [32]. 
The study conducted by Knuf et al. [32] on a group of 
123 adolescents (11-18 years), never vaccinated for 
pertussis, with negative anamnesis for pertussis and 
low anti-PT IgG titres, has shown that 29-49 days after 
administration of a single dose of dTpa vaccine, at least 
96% of the subjects had an immune response against all 
three antigens. 
Of the 78 initially seronegative for the anti-PT antigen, 
84.6% showed an immune response 29-49 das after vac-
cination. For the other antigens, the immune response 
was over 90%, regardless of the initial serological 
state [32]. 
In addition, a co-administration study has shown that the 
dTpa vaccine is immunogenic and well tolerated when 
co-administered, but at separate inoculation sites, with 
the bivalent anti-HPV vaccine, in youths aged 10-18 
years [33] (Figs. 6-8). 
Trials conducted in Australia, Belgium and Singapore 
in adults have shown high seroconversion rates and 
immune response towards pertussis antigens as well as 
towards tetanus and diphtheria [30], and antibody titre 
persistence up to 5 years after vaccination [34]. Mc-
Intyre et al. [34] in 2008 reported seroprotection rates 
towards diphtheria and tetanus of 94.4% and 96.2% 
respectively and seroconversion towards 3 pertussis 
antigens of between 89 and 100%. Anti-diphtheria 
and anti-tetanus antibody titres, up to 60 months af-
ter vaccination with dTpa, show how these remain 
significantly above the protection threshold and their 
equivalence to titres obtained after vaccination with 
Td [34].
Finally, the dTpa vaccine has also been evaluated for 
primary vaccination of adults in a study that enrolled 
460 subjects with mean age of 56.9 years, without dT 
vaccination for at least 20 years, or with an unknown 
vaccination history (51.5% of the total) [35]. 
The study has demonstrated that after 3 doses of dTpa 
vaccine, 99.3% and 100% of the subjects had seropro-
tective anti-diphtheria and anti-tetanus antibodies, while 
with regard to pertussis, a sharp increase in anti-pertus-
sis antibody titres has been observed after just 1 dose of 
vaccine, with rates of seroconversion equal to 92.2% to-
wards all three pertussis antigens (Fig. 9), showing that 
even in subjects that had never been vaccinated, contact 
with Bordetella pertussis induces an immunological 
Fig. 6. rates of seroconversion/seroprotection towards d, t, p, polio 1, 2, 3, hpv-16, hpv-18 in 751 youths vaccinated with dtpa-ipv + 
bivalent hpv 16,18 vaccine.
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memory that can be successfully boosted with a single 
booster dose [35].
Preventive strategies
In Italy, the 2005-2007 [36] National Immunization 
plan recommend a primary anti-pertussis cycle of three 
doses in the first year of life with a booster doses at 5-6 
years of age and evaluation of the opportunity for an ad-
ditional booster at 11-16 years. The target, with regard 
to anti-pertussis coverage, is the maintenance of high 
(> 95%) vaccination coverage, both for newborn infants 
and for the booster dose at 5-6 years.
In order to achieve the primary objective, which is 
control of the disease in infants with the greatest risk of 
complications, the administration of periodic pertussis 
booster to adolescents and adults, with reduced antigen-
content vaccines, in combination with anti-tetanus and 
anti-diphtheria, is under evaluation. 
However, at present, dT and dTpa booster vaccination 
coverage in adults is very low, as well as those in ado-
lescents, evaluated for the first time in 2008 within the 
scope of the ICONA study [11].
With regard to the 4th and 5th booster doses of anti-
tetanus and anti-diphtheria, coverage is 94 and 48% 
respectively, while it is definitely low for pertussis, 
being equal to 22 and 12% for the 4th and 5th doses re-
spectively [11]. 
Although universal adult vaccination is the most effective 
strategy for protecting the whole population [4], this does 
not seem realistically feasible. For this reason, in order to 
protect the subjects at greatest risk, many countries are im-
plementing strategies based on the vaccination of specific 
groups of adults (the parents of newborn infants, healthcare 
workers) as shown in Table III [37-40].
In 2001, the Global Pertussis Initiative (GPI) [4, 41] 
proposed 7 potential pertussis vaccination strategies, con-
sidering that the endemic nature of the disease, despite 
the good vaccination coverage, can be ascribed to loss of 
both natural and vaccine-induced immunity in the absence 
of booster doses. Among those preventive strategies, 
adolescents vaccination is very important as it has both 
the objective to protect the single and the community. In 
fact, it is well documented that the disease has re-emerged 
among adolescents and that the increasing circulation of 
Bordetella is a frequent cause of pertussis breakthroughs in 
schools. Moreover, adolescents could be a source of infec-
tion for unvaccinated siblings [42]. 
In Italy pertussis coverage among adolescents is con-
sistently low, even though different between regions. 
According to ICONA survey, the main reason is lack 
of information on advantages of vaccination among the 
families [11], who in the great part of Italy, do not re-
ceive any active call for dTap adolescent booster. 
However, adolescent booster, despite very important, is 
not enough to significantly reduce pertussis risk among 
infants, even with high coverage (> 75%). In fact, ac-
cording to a recent mathematical modelling study [43], 
reaching high coverage in adolescents has a direct ef-
fect on annual pertussis incidence among 10-19 years 
Fig. 7. Local adverse events occurring following administration of 
dtpa-ipv, hpv 16/18 and dtpa-ipv+ hpv 16/18. 
Fig. 8. Systemic adverse events occurring following administration of dtpa-ipv, hpv 16/18 and dtpa-ipv+ hpv 16/18.
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Fig. 9. immunogenicity of the dtpa vaccine in adults aged >40 years with unknown vaccination history or that had received their last dt 
booster over 20 years previously. rates of seroconversion and antibody titres towards the 3 pertussis antigens, prior to beginning the 
vaccination cycle and following administration of the 3 doses.
Tab. III. recommendations for pertussis vaccination in adolescents and/or adults in europe (adapted from Zepp et al., 2009 [40]). 
Country
Primary vaccination
(age months)
Booster dose Adult booster
Austria 2–4–6 12–24 months, 13–16 year 
belgium 2–3–4 15 months, 5–7 years, 14–16 years Cocoon strategy
Finland 3–5–12 4 years, 14–15 years - 
France 2–3–4 16–18 months, 11–13 years
27–28 years, all health care workers plus 
Cocoon strategy 
germany 2–3–4 11–14 months, 5–6 years, 9–17 years ≥18 years, Cocoon strategy, health care workers 
italy 3–5–11 5–6 years, 11–15 years - 
netherlands 2–3–4 11 months, 4 years - 
poland 2–4–6 16–18 months, 6 years - 
Switzerland 2–4–6 
15–24 months, 4–7 years,  
(11–15 years; catch-up) 
- 
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old subjects as well as a positive impact on newborn 
cases, but does not reduce the incidence of the disease 
in adults, that are still the main source of infection for 
susceptible infants.
Among the strategies proposed [4] to control pertussis, 
there is the “cocoon strategy”, envisaging the immuni-
sation of parents, family members and close contacts of 
newborns, within the prenatal period and in any case 
within 4 weeks of birth, with the aim to reduce the risk 
of transmission to susceptible newborns.
Although this strategy is far from ideal, as do not sig-
nificantly reduce circulation of Bordetella and do not 
generate a sufficient herd immunity, this strategy could 
be easier to carry out, compared to universal adult vac-
cination considering the greater ease of contacting and 
involving this group of subjects, that anyway are the 
most probable source in case of an eventual infection of 
the newborn infant.
The recent recommendations from ACIP [44] (Advi-
sory Committee on Immunization Practices) for the 
prevention of tetanus, diphtheria and pertussis in preg-
nant women or during the post-partum period and for 
newborn infants, consider that the majority of pertussis 
cases among newborn infants can be traced to parents, 
mainly the mother, further highlighting how the vac-
cination of both parents prior to hospital discharge 
from maternity department, may, according to math-
ematical models, reduce fatal cases by 38% [45]. The 
ACIP recommends that all women who have received 
the last Td vaccination at least 2 years earlier, be ad-
ministered a Tdap booster dose within the post-partum 
period [44]. 
According to the CDC [5], the availability of Tdap 
vaccines for adults offers the opportunity to reduce the 
spread of pertussis. In particular, replacement of Td 
vaccines with Tdap makes it possible to protect adoles-
cents and adults against pertussis, and above all reduce 
the circulation of the pathogen, allowing reduction of 
pertussis cases among at-risk subjects (e.g. newborn 
infants) and containment of the costs associated with 
the disease [5].
A recent mathematical modelling study [43], applied to 
data available in the Unites States, compared the impact 
of various pertussis vaccination strategies. The model 
has shown that vaccination of adolescents alone would 
lead to an initial reduction in the incidence of pertussis, 
but with the re-emergence of the disease in subsequent 
decades. The study shows that the most feasible strate-
gies are represented by infants and adolescents universal 
mass vaccination and periodic vaccination of all adults 
every 10 years (with a minimum coverage of 40%), or, 
as an alternative, in addition to infants and adolescents 
universal mass vaccination, vaccination of close con-
tacts (at least 65%) of newborn infants, in association 
with a booster dose for all adults, at the ideal age of 40, 
according to the model.
The last option could reduce by 2/3 pertussis cases 
among susceptible newborns [43].
In 2008 the ‘Cocoon strategy’ has been included in 
French ‘Guide des vaccination’ that, besides booster 
vaccination against pertussis to preschool children, ado-
lescents and adults, at the time of booster vaccination 
for tetanus and diphtheria, recommends a dTap booster 
for adults planning a pregnancy and the household, 
or alternatively, for the father and households during 
pregnancy, and, for the mother as soon as possible after 
delivery, as well as for healthcare workers coming into 
close contact with infants [37]. 
Similar recommendations have been inserted in Belgian 
and German (STIKO) Vaccination Plans [38, 39]. 
At present, only one experience of implementing Co-
coon strategy is available in the literature.
It is a study conducted in France [46] in a university 
maternity hospital showing that proper counselling of 
the parents about risks of pertussis infection and the 
benefits of booster vaccination as long as the recom-
mendation of immunization as soon as possible after 
discharge, is highly efficacious. After 3 months of ac-
tive campaign, during which 983 families have been 
informed during post-partum hospitalization, 68% of 
mothers and 63% of fathers were vaccinated, mostly in 
the first month after birth.
Hypothesis of adoption of the cocooning 
strategy in Italy
As already mentioned, the term “cocooning” means the 
vaccination strategy envisaging the indirect protection 
of newborn infants through the immunisation of a target 
adult/adolescent population, represented by the parents 
and other potential close contacts, such as siblings/cous-
ins, grandparents and healthcare workers. 
Within our organisational structure, the cocoon concept 
is based on the necessary interaction but in particular the 
coordination of various professionals, such as the health 
visitor, gynaecologist, general practitioner and paediatri-
cian, all potentially part of the cocooning strategy, but 
each operating within a separate healthcare context. Since 
this is a prevention plan, the local health unit (LHU) 
Prevention Department should have the responsibility for 
coordination of the various healthcare departments. On 
the other hand, the pregnant mother may be identified 
as the ideal linchpin in this collaboration, being central 
to its implementation within the territory. Indeed, it is 
reasonable to consider that the future mother, especially 
in the final months of pregnancy, centres all her energies 
on preparation for the birth and the future care of the 
newborn. Hence, if the pregnant mother is make aware of 
the problem of pertussis by specifically trained healthcare 
personnel, she will assume an active role in ensuring that 
the future contacts of the newborn verify their own vac-
cination status. 
Furthermore, the future mother may be involved more 
easily than the other contacts of the infant since she 
undergoes frequent medical check-ups and attends pre-
natal classes that may become the ideal venue for mak-
ing her aware of the importance of prevention, through 
vaccination, against certain infectious diseases that can 
have severe consequences for the newborn.
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Certainly, being among the first contacts, the healthcare 
personnel involved in the birth (gynaecologist, midwife, 
hospital paediatrician etc.) and with the infant in the 
early months (family paediatrician) should also be suit-
ably immunised against pertussis. Finally, if indicated, 
the pregnant mother herself should receive a booster 
vaccination, perhaps after the birth [44].
Therefore, if we consider the pregnant mother to be the 
operational linchpin of cocooning, we must consider the 
gynaecologist treating her and/or the Maternity Hospital 
(birth facility or equivalent structure), attended by the 
pregnant mother, as the healthcare facility where the 
first “step” in the process begins, namely the training 
and motivation of the pregnant mother.
The second “step” should envisage the pregnant mother, 
using the information with which she has been provided, 
endeavouring to sensitise the future family contacts al-
ready identified, inviting them to contact the healthcare 
authority vaccination clinic.
The third “step” would be the responsibility of the 
healthcare personnel at the vaccination clinic, who 
should implement a specific procedure for the admin-
istration of dTpa boosters to the future mother, after 
the birth, and her family members, registering them 
appropriately.
Naturally, both the family general practitioner and pae-
diatrician should be suitably informed of this strategy, 
contributing towards the proper operation by providing 
information on the disease and/or the vaccination to 
family members interested, or even playing an active 
role in promoting immunisation in families where there 
is an ongoing pregnancy. 
This organisational framework confirms that the 
LHU should be the healthcare structure responsible 
for the coordination of cocooning and evaluating 
the efficacy of the process. Indeed, the National 
Immunization Plan (NIP) [36] identifies the LHU 
as the operational structure allowing the practical 
implementation of vaccination coverage objectives, 
at the local level. Despite the organisational diversity 
existing in various situations, the structure that plans, 
organises and evaluates vaccination activity is solely 
the Prevention Department (PD). Indeed, at the entire 
LHA level, the PD has the responsibility for guaran-
teeing the attainment of the specific objectives of the 
various vaccination programmes, both national and 
regional. Again, according to the NVP, the PD also 
organises vaccine administration activities through 
the LHA medical and nursing staff. In particular, the 
PD is called to preside over priority areas, including 
vaccination awareness, the active and free offering 
of the vaccines envisaged in the regional calendar, 
the management of vaccination coverage and the 
reporting of infectious diseases, monitoring adverse 
events potentially attributable to vaccination and 
also the evaluation of the efficacy of vaccination 
programmes. Finally, we should remember that with 
the scope of ensuring the effective operation of the 
network, the NIP aims to actively involve other LHU 
services, namely the Districts, family paediatricians, 
general practitioners, hospital and outpatient special-
ists.
With regard to the present project, in LHUs opting for 
the cocooning strategy to reduce the risk of pertussis in 
newborn infants, the PD might implement the following 
actions:
• training of a multidisciplinary working party (repre-
senting the health worker, gynaecologist, midwife/
Maternity Hospital, general practitioner and hospital 
and family paediatrician); 
• definition of the project and drafting of a process 
document by the working party;
• definition of the indicators of management efficiency 
(e.g. percentage of vaccinated subjects per pregnant 
mother, number of training operations performed, 
user surveys ecc.) and outcome that are actually 
measurable (cover, adverse events, degree of user 
satisfaction); 
• the development of cognitive tools (training materi-
als for healthcare staff, booklets for mothers/fami-
lies); 
• presentation of the project within the LHU: staff 
meetings; 
• presentation of the project outside the LHU (meet-
ings with gynaecologists/healthcare staff/GPs, PD/
working party press conference with local/regional 
press and television);
• vaccination of hospital staff/healthcare staff (in con-
tact with newborn infants) adhering to the project;
• educational materials for pregnant mothers/fertile 
women distributed through strategic locations (Ma-
ternity Hospitals, prenatal courses, LHU clinics, 
gynaecology clinics/healthcare facilities/GPs);
• evaluation (after a suitable period of time) of the 
process and outcome indicators envisaged for the 
project and production of a report;
• periodic communication of the results: publica-
tion in relevant scientific journals; PD/working 
party press conference with local/regional press 
and television.
By virtue of its scientific content and prerequisites, 
‘cocooning’ might also constitute a training project in 
accordance with CME criteria. Once accredited, the 
participants in this project should thus obtain train-
ing credits annually, in relation to the operation of 
the project within the structure of origin in addition 
to personal learning (as a further incentive). Start-up 
and operational maintenance of the project requires 
training meetings and periodic meetings with the 
participating healthcare workers dedicated to training/
learning and discussion of the operating criteria. The 
contribution of individual healthcare workers towards 
the right implementation of the project should be re-
ported to the competent bodies and personnel depart-
ments and made public during periodic publishing of 
the results of the project itself.
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Conclusions 
European and Italian epidemiological data demonstrate 
how, despite the high vaccination coverage achieved 
during the first year of life, pertussis is not perfectly 
controlled in newborn infants that have not yet been 
vaccinated due to the circulation of the pathogenic agent 
and the shift of the disease to adult age.
Besides universal adult vaccination, in order to reduce 
the risk of pertussis in newborn infants, the subjects at 
greatest risk of hospitalisation and severe complications, 
the vaccination of the contacts closest to the newborns 
(cocooning strategy) has been proposed.
According to this considerations and to the operational 
models described above, cocooning would appear to be 
an achievable plan by Public Health Department. Indeed, 
to put the plan into practice, a great deal of determination 
by the LHU management, substantial work by the health-
care workers involved (especially to start up the project), 
the availability of the planning and implementation tools 
identified by the working party, in addition to a positive 
and capable administration framework, is required.
This project would also have the great additional value 
of sensitising adults to vaccination boosters and increas-
ing anti-tetanus and anti-diphtheria vaccination cover-
age, in compliance with Pres. Decree No. 1301 of 7 Sep-
tember 1965, in accordance with which revaccinations, 
through the administration of tetanus anatoxin, possibly 
in combination with diphtheria anatoxin and/or with 
other antigens, are conducted at 10 year intervals [47].
Indeed, recent seroepidemiological data shows that, in 
Italy, 40% of males over the age of 30 years and 60% 
of females have anti-tetanus antibody titres that are 
considered non-protective [48], while, with regard to 
diphtheria, over 20% of adults over the age of 40 years 
are unprotected [49].
References
[1] Tan T, Trindale E, Skowronski D. Epidemiology of pertussis. 
Pediatr Infect Dis J 2005;24:S10-S18.
[2] de Melker H, Versteegh F, Schellekens J, Teunis PF, 
Kretzschmar M. The incidence of Bordetella pertussis infec-
tions estimated in the population from a combination of sero-
logical surveys. J Infect 2006;53:106-13.
[3] Galanis E, King A, Varughese P, Halperin SA; IMPACT inves-
tigators. Changing epidemiology and emerging risk groups for 
pertussis. CMAJ 2006;174:451-2.
[4] Forsyth KD, Wirsing von Konig CH, Tan T, Caro J, Plotkin 
S. Prevention of pertussis: reccomendations derived from the 
second Global Pertussis Initiative roundtable meeting. Vaccine 
2007;25:2634-42.
[5] Centers for Disease Control and Prevention. Preventing teta-
nus, diphtheria, and pertussis among adults: use of tetanus 
toxoid, reduced diphtheria toxoid and acellular pertussis 
vaccine: recommendations of the Advisory Committee on Im-
munization Practices (ACIP). MMWR 2006;55 (December 
15, 2006).
[6] Wood N, Quinn HE, McIntyre P, Elliott E. Pertussis in infants: 
Preventing deaths and hospitalisations in the very young. J 
Paediatr Child Health 2008;44:161-5.
[7] Edwards KM, Decker MD. Pertussis vaccine. In: Plotkin S, 
Orenstein WA, eds. Vaccines. 4th ed. Philadelphia, PA: Saun-
ders Co. 2004, pp. 471-528.
[8] The Italian Vaccine Coverage Survey Working Group. Child-
hood vaccination coverage in Italy: results of a seven-region 
survey. Bull World Health Org 1994;72:885-95.
[9] Binkin NJ, Salmaso S, Tozzi AE, Scuderi G, Greco D, Greco 
D. Epidemiology of pertussis in a developed country with low 
vaccination cover-age: the Italian experience. Pediatr Infect 
Dis J 1992;11:653-61.
[10] Salmaso S, Rota MC, Ciofi degli Atti ML, Tozzi AE, Kreidl 
P, the ICONA Study Group. Infant immunization coverage in 
Italy: estimates by simultaneous EPI cluster surveys of regions. 
Bull World Health Org 1996;77:843-51.
[11] ICONA 2008: Indagine di Copertura vaccinale Nazionale 
nei bambini e negli adolescenti. Reports ISTISAN: 09/29. 
www.iss.it
[12] Rota MC, D’Ancona F, Massari M, Mandolini D, Giammanco 
A, Carbonari P, et al. How increased pertussis vaccination 
coverage is changing the epidemiology of pertussis in Italy. 
Vaccine 2005;23:5299-305.
[13] Gabutti G, Bergamini M, Bonanni P, Guido M, Fenoglio D, 
Giammanco A, et al. Assessment of humoral and cell mediated 
immunity against Bordetella pertussis in adolescent, adult and 
senior subjects in Italy. Epidemiol Infect 2008;136:1576-84.
[14] Wirsing von König CH, Halperin S, Riffelmann M, Guiso N. 
Pertussis of adults and infants. Lancet Infectiuous Diseases 
2002;2:744-50.
[15] Cherry JD. The epidemiology of pertussis: a comparison of the 
epidemiology of the disease pertussis with the epidemiology of 
Bordetella pertussis infection. Pediatrics 2005;115:1422-7.
[16] Wood N, McIntyre P. Pertussis: review of epidemiology, di-
agnosis, management and prevention. Paediatric Respiratory 
Reviews 2008;9:201-12.
[17] http://www.ministerosalute.it/programmazione/sdo/sdo.jsp 
[18] Cuccia M. La necessità di continuità nella protezione vaccinale 
contro la pertosse: il contagio dall’adolescente/adulto al neo-
nato. J Prev Med Hyg 2004;45(Suppl. 1):8-10.
[19] Celentano L, Massari M, Paramatti D, Salmaso S, Tozzi AE; 
EUVAC-NET Group. Resurgence of pertussis in Europe. Pedi-
atr Infect Dis J 2005;24:761-5.
[20] Horcajada Herrera I, Hernández Febles M, González Jorge R, 
Colino Gil E, Bordes Benítez A, Pena López MJ. Epidemiol-
ogy and clinical study of Bordetella pertussis in Gran Ca-
naria Island, Spain, in the period 2003-2007. An Pediatr (Barc) 
2008;69:200-4. 
[21] Bonmarin I, Bouraoui L, Guiso N, Levy-Bruhl D. Pertus-
sis: data collection and vaccinal strategy. Med Malad Infect 
2009;39:271-7.
[22] Centers for Disease Control and Prevention. Pertussis: 
United States, 2001-2003. MMWR Morb Mortal Wkly Rep 
2005;54:1283-6.
[23] Hewlett EL. Pertussis: current concepts of pathogenesis and 
prevention. Pediatr Infect Dis J 1997;16:S90-S96. 
[24] Bamberger ES, Srugo I. What is new in pertussis? Eur J Pediatr 
2008;167:133-9.
[25] Esposito S, Agliardi T, Giammanco A, Faldella G, Cascio 
A, Bosis S, et al. Long-term pertussis-specific immunity after 
primari vaccination with a combined diphtheria, tetanus, 
tricomponent acellular pertussis, and hepatitis B vaccine in 
comparison with that after natural infection. Infect immune 
2001;69:4516-20.
[26] Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration 
of immunity against pertussis after natural infection or vacci-
nation. Pediatr Infect Dis J 2005;24:S58-61.
F. bLAngiArdi, g. FerrerA
216
n	 Received on November 20, 2009. Accepted on December 10, 2009.
n Correspondence: Giuseppe Ferrera, Epidemiology Service, Ragu-
sa LHA, via Giuseppe di Vittorio 59/c, 97100 Ragusa, Italy - E-
mail: servizio.epidemiologia@asp.rg.it
[27] Poolman JT, Hallander HO. Acellular pertussis vaccines 
and the role of pertactin and fimbriae. Expert Rev Vaccines 
2007;6:47-56.
[28] Jefferson T, Rudin M, Di Pierantonj C. Systematic review 
of the effects of pertussis vaccines in children. Vaccine 
2003;21:2003-14.
[29] Framton JE, Keating GM. Reduced-antigen combined diph-
theria, tetanus and acellular pertussis vaccine (Boostrix). A 
review of its use as single-dose booster immunization. Bio-
drugs 2006;20:371-89.
[30] Di Pasquale A. dTpa-IPV: un nuovo vaccino combinato Glaxo-
SmithKline per nuove esigenze e prospettive nella Sanità Pub-
blica. J Prev Med Hygiene 2004;45(Suppl.1):11-3.
[31] Pichichero ME, Casey JR. Acellular pertussis vaccines for 
adolescents. Pediatr Infect Dis J 2005;24:S117-S26.
[32] Knuf M, Zepp F, Meyer C, Grzegowski E, Wolter J, Riffel-
mann M, et al. Immunogenicity of a single dose of reduced an-
tigen acellular pertussis vaccine in non-vaccinated adolescent 
population. Vaccine 2006;24:2043-8.
[33] Schwarz TF, Garcia-Sicilia J, Carmona A, Malkin JE, Tran M, 
Peters K, et al. Co-administration of AS04-adjuvanted HPV-
16/18 cervical cancer vaccine with dTpa-IPV in 10-18-year-old 
girls: month 7 results from a randomized trial. Poster presented 
at 27th ESPID, Brussels, 9-13 June 2009.
[34] McIntyre PB, Burgess MA, Egan A, Schuerman L, Hoet B. 
Booster vaccination of adults with reduced-antigen content 
diphtheria, tetanus and pertussis vaccine: immunogenicity 5 
years post-vaccination. Vaccine 2009;27:1062-6.
[35] Theeten H, Rümke H, Hoppener FJ, Vilatimó R, Narejos 
S, Van Damme P, et al. Primary vaccination of adults with 
reduced antigen-content diphtheria-tetanus-acellular per-
tussis or dTpa-inactivated poliovirus vaccines compared 
to diphtheria-tetanus-toxoid vaccines. Curr Med Res Opin 
2007;23:2729-39.
[36] Conferenza permanente per i rapporti tra lo Stato, Regioni e 
le Province Autonome di Trento e Bolzano. Determinazione 3 
marzo 2005. Accordo ai sensi dell’art 4 del decreto legislativo 
28 agosto 1997, n. 281, tra il Ministro della salute e i Presidenti 
delle regioni e delle province autonome, concernente il Nuovo 
Piano Nazionale Vaccini 2005-2007. GU n. 86 del 14-04-2005 
- Suppl ordinario n.63. 
[37] Recommendation: Conseil Supérieur d’Hygiène Belgique, Feb-
ruary 2008.
[38] Calendrier Vaccinel 2008 - Bulletin Epidemiologique Heb-
domadaire - n. 16-17, April 2008.
[39] Robert-Koch-Institut and STIKO- Epidemiologisches Bullettin 
n. 30, 28 July 2006.
[40] Zepp F, Bernatowska E, Guiso N. Heininger U, Mertsola J, 
Roord  J, et al. Consensus on Pertussis Booster Vaccination in 
Europe (C.O.P.E). Poster presented  at 27th ESPID, Brussels, 
9-13 June 2009.
[41] Campins-Martì M, Cheng HK, Forsyth K, Guiso N, Halperin S, 
Huang LM, et al. Recommendations are needed for adolescent 
and adult pertussis immunization: rationale and strategies for 
consideration. International Consensus Group on Pertussis Im-
munisation. Vaccine 2001;20:641-6.
[42] Sin MA, Zenke R, Rönckendorf R. et al. Pertussis outbreak in pri-
mary and secondary schools in Ludwigslust, Germany demonstrat-
ing the role of waning immunity. Ped Infect Dis J 2009;28 :242-4.
[43] Coudeville L, Van Rie A, Andre P. Adult pertussis vaccination 
strategies and their impact on pertussis in the United States: 
evaluation of routine and targeted (cocoon) strategies. Epide-
miol Infect 2008;136:604-20.
[44] MMWR (Morbidity and Mortality Weekly Report) May 30, 
2008 / Vol. 57 / No. RR.
[45] Scuffham PA, McIntyre PB. Pertussis vaccination strategies 
for neonates - an exploratory cost-effectiveness analysis. Vac-
cine 2004;22:2953-64.
[46] Leboucher B, Sentilhes L, Henry E, El Baba D, Montcho Y, 
Abbou F.  Impact of postpartum information about pertussis 
booster to parents in a university maternity hospital. Poster 
presented at 27th ESPID, Brussels, 9-13 June 2009.
[47] Presidential Decree No. 464 of 7 November 2001, Official 
Gazette No. 7 of 09 January 2002.
[48] Pedalino B, Cotter B, Ciofi degli Atti M, Mandolini D, Par-
roccini S, Salmaso S. Epidemiology of tetanus in Italy years 
1971-2000. Euro Surveill 2002;7:103-10.
[49] Edmunds WJ, Pebody RG, Aggerback H, Baron S, Berbers 
G, Conyn-van Spaendonck MA, et al. The sero-epidemiol-
ogy of diphtheria in Western Europe. Epidemiol Infect 
2000;125:113-25.
